Primary Dysmenorrhea - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 37 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Primary Dysmenorrhea - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Primary Dysmenorrhea - Pipeline Review, H2 2014', provides an overview of the Primary Dysmenorrhea's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Primary Dysmenorrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Dysmenorrhea and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Primary Dysmenorrhea
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Primary Dysmenorrhea and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Primary Dysmenorrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Primary Dysmenorrhea pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Primary Dysmenorrhea
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Primary Dysmenorrhea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Primary Dysmenorrhea Overview 6
Therapeutics Development 7
Pipeline Products for Primary Dysmenorrhea - Overview 7
Pipeline Products for Primary Dysmenorrhea - Comparative Analysis 8
Primary Dysmenorrhea - Therapeutics under Development by Companies 9
Primary Dysmenorrhea - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Primary Dysmenorrhea - Products under Development by Companies 12
Primary Dysmenorrhea - Companies Involved in Therapeutics Development 13
Merck & Co., Inc. 13
PDC Biotech GmbH 14
Jiangsu Kanion Pharmaceutical Co., Ltd. 15
Primary Dysmenorrhea - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
KYG-0395 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
etonogestrel Vaginal Ring - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
PDC-31 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Peptidometics - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
PDC-41 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Primary Dysmenorrhea - Recent Pipeline Updates 30
Primary Dysmenorrhea - Dormant Projects 31
Primary Dysmenorrhea - Product Development Milestones 32
Featured News & Press Releases 32
Dec 10, 2012: PDC Biotech Completes Phase I Study Of PDC31 For Treatment Of Preterm Labor 32
Nov 01, 2012: Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related To Vioxx 32
Nov 15, 2010: PDC Biotech announces start of Phase l trial - novel peptide for treatment of preterm labour and primary dysmenorrhea 33
Jan 05, 2010: China Aoxing Pharmaceutical Announces Successful Completion Of Phase II Clinical Study Of TJSL For The Treatment Of Primary Dysmenorrhea 33
Feb 26, 2008: Sciele Pharma, Inc. Reports Results for Fourth Quarter and Year Ended December 31, 2007 33
Oct 30, 2007: Sciele Pharma, Inc. reports revenues and earnings for the third quarter of 2007. 34
Jul 25, 2007: Sciele Pharma, Inc. Reports Revenues and Earnings for the Second Quarter 2007 34
Apr 26, 2007: Sciele Pharma, Inc. reports results for the first quarter of 2007. 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables
Number of Products under Development for Primary Dysmenorrhea, H2 2014 7
Number of Products under Development for Primary Dysmenorrhea - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Primary Dysmenorrhea - Pipeline by Merck & Co., Inc., H2 2014 13
Primary Dysmenorrhea - Pipeline by PDC Biotech GmbH, H2 2014 14
Primary Dysmenorrhea - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2014 15
Assessment by Monotherapy Products, H2 2014 16
Number of Products by Stage and Target, H2 2014 18
Number of Products by Stage and Mechanism of Action, H2 2014 20
Number of Products by Stage and Route of Administration, H2 2014 22
Number of Products by Stage and Molecule Type, H2 2014 24
Primary Dysmenorrhea Therapeutics - Recent Pipeline Updates, H2 2014 30
Primary Dysmenorrhea - Dormant Projects, H2 2014 31